GPC5 and hepatocellular carcinoma: The up-regulation of GPC-5 at the mRNA level had no relationship with the OS for HCC patients (P > 0.05, Fig. 4e), whereas such an up-regulation exhibited a favorable effect on OS in hepatitis virus HCC, sorafenib treatment group (HR = 0.42, 95% CI = 0.21–0.85, P = 0.0125, Fig. 8e; HR = 4.56, 95% CI = 0.94–22.27, P = 0.0439, Supplemental Table 3).